Principle Wealth Partners LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Principle Wealth Partners LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 10.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,422 shares of the company’s stock after purchasing an additional 620 shares during the period. Principle Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $3,744,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of LLY. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the fourth quarter valued at $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company in the third quarter valued at $27,000. Legacy Financial Group LLC purchased a new stake in Eli Lilly and Company in the third quarter valued at $35,000. Optiver Holding B.V. purchased a new stake in Eli Lilly and Company in the third quarter valued at $36,000. Finally, Family CFO Inc purchased a new stake in Eli Lilly and Company in the third quarter valued at $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Truist Financial restated a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Bank of America lifted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

LLY traded up $8.64 on Friday, hitting $733.51. 2,009,249 shares of the company were exchanged, compared to its average volume of 2,265,427. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business’s fifty day moving average is $761.79 and its 200 day moving average is $666.67. Eli Lilly and Company has a fifty-two week low of $380.77 and a fifty-two week high of $800.78. The firm has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the company posted $2.09 EPS. The company’s revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.